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It is no secret that the pharmaceutical industry is undergoing rapid
and revolutionary change. The impact of managed care and
threatened pricing caps by the US Congress on new products has
caused many companies to re-evaluate their short and long term
business and research strategies. In too many cases, this has resulted
in down-sizing by both lay-os and attrition. For most analytical
laboratories, this has meant doing more with less resources. There
are several major ’realities’ that are having a significant influence
on the amount and type of analytical support required to bring a
new product to the market place in today’s regulatory climate. They
are pre-approval inspections, the Barr decision and the proposed
ICH guidelines. Other realities of the 1990s are also influencing
the operation of the analytical laboratory. To cope with these
realilies, wise use of resources is mandatory. The strategies
employed by each company differ, but laboratory automation is
usually one ofthe important elements ofthe equation. Other elements
include contract laboratories, consultants and temporaries. Each of
lhese elemems provides part of the solution to doing more with less,
bul each has its own positives and negatives which must be
considered. This paper looks at the relationships between these
factors and their impact on the analytical laboratory.
Introduction
Forty per cent of this decade is already in the history
books. For those of us in the health care business and
other related industries the ’realities’ of the 1990s and
beyond are coming into focus. Unfortunately, the picture
is not always encouraging or reassuring. Too many times
we hear or read about different companies reducing their
payroll, or divesting themselves ofunprofitable businesses,
or merging, or restructuring. Regardless ofthe words used,
the work force is usually being decreased. We also hear
and read about new regulations being imposed on business
by the local, state and federal governments. Many of these
new regulations increase the cost of goods. The cost
increase is always passed on to us, the consumer, pushing
up the cost of living. That is reality!
have been in the pharmaceutical industry for over 30
years and never has the attack on the pharmaceutical
industry been as intense as it is now. To be opposed to
the pharmaceutical industry is politically correct. In
autumn 1994, the US Congress shelved voting on a health
care bill until at least 1995. What impact a health care
bill will have on drug prices and health care costs is
uncertain, but, if history has taught us anything, once
Washington gets involved things get worse and the costs
go up.
Three of the biggest realities (figure 1) currently having
an impact on the pharmaceutical industry are pre-
Pre-approval inspections
Barr decision
ICH guidelines
Figure 1. Realities for the 1990s and beyond.
approval inspections, the Barr decision and the ICH
guidelines.
Realities of the 1990s
Pre-approval inspections
The generic drug scandal greatly increased the number
of pre-approval inspections by the FDA in the USA. The
legal authority to conduct these inspections is well-
established by the FD&C Act and by the Agency’s policies
(figure 2). The objectives ofPolicy 7346.832 [ 1] are shown
in figure 3. Essentially, the FDA wants to be sure that
the firm adheres to cGMPs, can manufacture the product
as described in the NDA, has accurate data on the
bio-batches and can verify the firm’s results themselves.
FDA wants to do this within 45 days of accepting the
NDA for filing (figure 4). I do not know if FDA has
actually inspected anyone within 45 days, but they have
within 90 days. In my company, this has had a great
impact. It is our policy to have completed process
validation reports within the 45-day window on three
full-scale batches for all manufacturing sites that are
Section 704(a)(1) of FD&C Act
Compliance policy guide No. 7346.832--
issued October 1990
Generic drug scandal increased the number of
pre-approval inspections
Figure 2. FDA legal authority for pre-approval inspection.
Evaluation of firm’s compliance to
cGMP’s, including specific batches
used to demonstrate bioequivalence
(biobatches)
Evaluation if firm has adequate
facilities, equipment, procedures
and controls to manufacture product
as described in the application
Audit the accuracy of the biobatch
manufacturing and testing information
submitted in the application
Collection of a sample of the biobatch
from the bioequivalence test laboratory
Figure 3. Objectives of CP 7346.832.
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Have a field pre-approval inspection
within 45 days of acceptance of the
NDA filing by the FDA
Figure 4. FDA goal.
included in the NDA. Five years ago we used to do this
about six months before we expected FDA approval of
the NDA. This creates a lot of routine assay work and
requires a significant commitment of resources much
earlier than in the past.
The FDA’s expectations during the inspection are shown
in figure 5. These expectations are not unreasonable, yet
we know that a significant number of firm’s applications
have not been approved as a result of the pre-approval
inspection. I can’t emphasize enough the need for good
documentation. The FDA wants to see documentation.
Can you prove you did it in accordance with your SOPs?
The FDA’s approach to the inspection is spelled out in
the FDA’s Laboratory Inspection Guide [2], which was
published in June 1992. Some of the areas that will be
inspected are shown in figure 6.
One important area is the increased scrutiny that the FDA
is giving to methods validation. According to the June
1994 issue of The Gold Sheet [3] about one-third of recent
drug GMP warning letters have cited concerns involving
the use ofanalytical methods. Besides inadeqdate methods
validation, the FDA is also citing companies on how they
handle records, procedures, equipment, reference stan-
dards and samples.
Firms provide adequate assurances that
drugs have the following features that they
purport to have
Identity
Quality
Purity
Strength
Good science used
Complete documentation available
Figure 5. FDA expectations.
Bulk drug substances
Microbiological data
Sampling
Laboratory records and documentation
Laboratory standard solutions
Methods validation
Equipment
Raw material testing
In-process control and specifications
Quality of data
Stability
Sampling protocols
Computerized laboratory data acquisition systems
Laboratory management
Laboratory Inspection Guide (22 June, 1992)
Figure 6. Inspection approach.
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The Barr decision
On February 4th, 1993 Judge Wolin ruled on the case of
the USA versus Barr Laboratories. Essentially Judge
Wolin interpreted the GMPs. Some of the key areas he
interpreted are shown on figure 7. The most controversial
areas are probably retesting, resampling, averaging and
using outlier tests to reject data. Judge Wolin essentially
issued a set of rules about how out-of-specification
laboratory results are to be handled. Out-of-specification
results were divided into three classes (figure 8) document-
able laboratory error, non-process related or operator
error and process related or manufacturing process error.
Laboratory error is the easiest to deal with and requires
only an informal investigation. The other two, however,
require a formal investigation and involve other areas,
since the cause may be due to process issues. As a result,
retesting or resampling cannot be automatically per-
formed. In fact, he stated that resampling is always
suspect. Defendable, documented reasons and decisions
are required to retest and resample. The use of scientific
judgement in the decision-making process is discussed by
Judge Wolin. The decisions resulting from retesting and
resampling must be documented and approved by the
’appropriate’ level ofmanagement. Some FDA personnel
mean your CEO, because they will hold him/her
accountable.
This decision has a big impact on the operation of the
analytical laboratory. Any GMP/GLP activity is covered
by the Barr decision. Other activities are not. The FDA
will tell you that work on developmental compounds are
excluded, but, drug safety supplies, clinical supplies and
process validation samples are. The result is that everyone
in the laboratory has to be aware of the type of sample
they are assaying and, if an out-of-specification result is
Out-of-specification (OOS) laboratory results
USP standards
Retesting
Resampling
Averaging assay results
Methods validation
Outlier statistical tests
Blend testing
Product release
Remixing
Validation criteria
Cleaning validation
Figure 7. Barr decision.
Three possible categories:
(1) Laboratory error
Analyst error with assignable cause
Informal investigation and documentation
(2) Non-process related or operator error
(3) Process related or manufacturing process error
(2) and (3) require formal investigation outside of the
laboratory and formal documentation of findings and
decisions
Figure 8. Out-@specification laboratory results.P. A. Lane, ISLAR 1994
Harmonization of stability requirements
Detection and control of lower levels of
impurities and degradation products
0-1% or mg/day intake (whichever is less)
if less than 2 g/day
0-05% if more than 2 g/day
Faster submissions
File with one year stability data
at 30C/60o R H
Figure 9. ICH guidelines.
obtained, the correct response occurs. My advice is to
have an SOP, because the FDA is looking to see how you
handle this. The FDA has taken the Judge’s ruling and
is using it when they inspect.
If you have not read the entire 88 page decision, you
should. It is very interesting and easy to read. You might
read about something you are doing which the Judge has
interpreted as being unacceptable.
ICH guidelines
Another reality facing the pharmaceutical analyst is the
proposed ICH guidelines (see figure 9). The goal of the
ICH guidelines is to harmonize submission requirements
between the USA, Europe and Japan.
The stability guidelines [4-] have essentially been agreed
to. You will be able to file with 12 months at 30C/60
RH data. This will put the analytical laboratory on the
critical path to complete these assays as quickly as possible.
The guidelines [5] on impurities and degradation
products will also require that more sensitive and rugged
methods be used. The proposed guideline states that, if
2 g or less of a drug is taken daily, then the impurities
and degradation products must be controlled at the 0"1
level. If the daily dosage exceeds 2 g, then the impurities
and degradation products must be controlled at the 0"05
level. In most cases this will mean that more sophisticated
methods will be employed, requiring a highly trained staff,
more time and more money.
Additional realities of the 1990s
These three realities by themselves will require more
resources to get the job done with the quality and speed
that top management wants. Besides the three realities
already discussed, there are several more realities that face
us through the rest ofthe decade and into the 21st century.
These are shown in figure 10.
Down-sizing and mergers
Diverse work force
Work and family programmes
IQ/OQ initiatives
Figure 10. More realities for the 1990s.
Do more with less--Faster
Age of unreason:
Core workers
Consultants
Temporaries
Contract services
Figure 11. Down-sizing and mergers.
Down-sizing and mergers
All too frequently the media tell us about companies
down-sizing, about mergers, about re-structuring and
about early voluntary retirement programmes (figure 11 ).
There is a very high probability that we all will experience
this during our careers. The annual chemist’s salary survey
published in the 11 July issue of Chemical And Engineering
News [6] says that the job market for chemists in the USA
is the weakest in 20 years. Salary gains also dipped.
The big challenge is how to manage an increasing
workload with decreasing work staff. Some companies
have increased their use of contract laboratories. Some
have increased their use of temporaries and consultants.
Many companies are doing both. In 1990, Professor
Charles Handy of the Harvard Business School published
a book, entitled The Age Of Unreason [7]. In this book
Professor Handy describes the company of the future. It
will consist of a small group of core workers who conduct
the company business using contract firms, temporaries
and consultants. The good news for people like us is that
the technical and scientific staff are considered core
workers by Professor Handy. The core workers would
actually be employees of the company, but the tem-
poraries and consultants would be self-employed and
would work for the company only when the company
needed them. An article in the 6 March New York Times
[8] agreed with this. Protissor Handy says this is the
future, but, in my company and in many others, this is
happening right now. The future is now.
Professor Handy also said that most people’s careers at a
company would end at about age 50. This would allow
for young people with new ideas to join the company as
core workers. Maybe the voluntary early retirement
programmes are the first sign of this prediction. Nonethe-
less, the challenge is to do more with less--faster.
Diverse work force
The demographics say that the composition of the work
force is changing (figure 12). The latest analysis of the
composition of the United States work force shows that
the number of women and minorities in science is slowly
increasing. According to an article in Today’s Chemist At
Work [10] by the year 2000 white males will only be 49
of the work force. The way we work and how we think
about work is changing. The work ethic is different in
different cultures and the successful manager has to learn
how work in the new environment. The manager will
have to promote team work among diverse workers. How
the manager does this will be scrutinized to be sure that
the manager is not biased. So, the manager will have to
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Work force is changing:
By 2000 white males less than
50%, of work force
20% increase in Hispanics in science
since 991
Women represent 10% of science work
force since 1991
Work ethic is changing
Teamwork
Figure 12. Diverse work force.
be able to effectively use the diverse work force to meet
the company’s goals within the established time line.
Work andfamily programmes
Work and family programmes (figure 13) are excellent
programmes that help everyone cope with family needs.
They do present challenges, however. Programmes, such
as flex time and flex place, as helpful as they are, can
be abused. With flex time, it is difficult sometimes to
know that the employee worked a thll day. With flex
place the manager has to trust the employee is working
his/her full day at home. When headcount is being
reduced, or is remaining constant, and the workload is
increasing, the potential loss in productivity created by
flex time and place can be problematic if deadlines are
crucial. Programmes for child care and care for aged
parents also present problems tbr the manager. A sick
child or parent can legitimately require an employee to
be absent, but can cause loss of productivity.
The New Jersey Clean Air Act is an example of a
state-mandated programme to reduce the number of
single passenger automobiles on the road during rush
hour, by forcing car pooling. This means the employee
will leave when their car pool leaves, even if the employee
has not completed their day’s assignments. I wonder how
productivity will suffer when this becomes law in 1996?
IQ/oQ initiatives
All of the various qualification initiatives (figure 14) are
becoming reality. The FDA wants documentation to
prove that the instruments are functioning as expected.
My regulatory group wants me to write an installation
qualification protocol to document that the new instru-
ment was installed correctly and meets the vendor’s
specifications. If I had enough staff, ! might entertain this
request. am not convinced that this adds value to the
data. I think that there are better ways to ensure the
quality and integrity of the data.
Flex time
Flex place
Child care
Care for aged parents
Federal Clean Air Act
Figure 13. Work andfaro@ programmes.
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Installation qualification (IQ)
Operations qualification (OQ)
IQ--process of demonstrating instrument performs
its intended functions within its specified tolerances
OQ--process of demonstrating a sequence of analytical
operations behaves as expected
Figure 14. IQ/OQ. initiatives.
Where are we going with all of these initiatives? Are we
going to have an instrument check list that the chemist
will initial for every step he performs? One of my
regulatory colleagues keeps telling me that there will be
analytical ’batch’ sheets, similar to a manuttcturing batch
record, where every step the chemist performs will be
verified by a second individual.
Survival in the 1990s and beyond
Each of these realities presents formidable challenges to
being efficient and highly productive for the remainder
of the decade and into the next century. In fact your very
survival as an organization may depend on how you
respond to these realities. So, how are we going to survive?
How are we going to do more with less resources? How
are we going to do it faster? If Professor Handy is correct,
we certainly will be using consultants, temporaries and
contract service organizations to help us accomplish our
objectives.
Decision-making will be crucial to survival. Management
will have to make hard decisions about projects and stick
to them. No organization will be able to afford spending
resources on projects that do not have significant return
on the investment. For example, probably no pharma-
ceutical company will be able to successfully market a
number four ’me-too’ product in the managed care
environment we are entering. In the past, companies could
do this and make big profits. Companies will have to
carefully monitor their development portfolios and
terminate projects if market forces require it.
Data flow will be crucial to survival. The most important
product that the analytical chemist produces is accurate,
reproducible data. If the data do not get to the right
person at the right time no decision or, even worse, a bad
decision could be made. LIMS will become very im-
portant to the organization. The company that can
gather, process and evaluate data quickly will have a
market advantage over the company that cannot,
especially if they compete in the same markets. In my
company we are implementing a new LIMS that will
connect all of our worldwide sites so that we can instantly
share data. This will allow us to make better decisions
faster and will shorten cycle time for worldwide regulatory
submissions and inquiries.
Finally, automation will be crucial to survival. I do not
need to preach about the value of robotics in this journal.
I will not cite productivity data. However, I will call your
attention to an editorial in the June 1994 issue of
Pharmaceutical Technology [11-] by Francis Zenie, President
of Zymark. In this excellent editorial Mr Zenie discussesP. A. Lane, ISLAR 1994
1. Increases capacity for significantly higher
sample loads and more complex testing on
each sample
2. Provides just-in-time analysis for faster
new product introduction, timely correction
of quality control problems and enhanced
customer service.
3. Enhances precision, documentation and
defensible audit trails.
4. Reduces analysis cost while routinely
gathering all the data necessary to solve
problems quickly--rather than wait for
more data.
5. Transfers valid analytical methods to
multiple sites worldwide.
6. Improves motivation, reduces turnover
and enhances the effectiveness of a down-sized
work force.
7. Utilizes valuable laboratory space more
effectively.
Figure 15. Francis Zenie’s seven benefits of highly effective
laboratory automation.
’The seven benefits of highly effective laboratory auto-
mation’. The seven benefits are shown in figure 15. The
seven benefits provide some of the answers to how to do
more with less--faster.
Summary
We can look at the realities we face and be pessimistic
about the future or we can look at them as an opportunity.
I look at them and see opportunities and cbaiienges.
Opportunities and challenges that will make us extend
ourselves, make us think outside of the box, make us
challenge the conventional thinking, make us go where
no one has gone before. Things will change, so let us shape
the realities of the future and not let someone else shape
it for us.
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